Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 52-Week High – Time to Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $40.00 and last traded at $40.0980, with a volume of 3519760 shares trading hands. The stock had previously closed at $27.58.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CNTA. TD Cowen restated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Needham & Company LLC reiterated a “hold” rating on shares of Centessa Pharmaceuticals in a research note on Tuesday. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, B. Riley Financial raised their price objective on Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $40.00.

Centessa Pharmaceuticals Stock Performance

The company has a market cap of $5.82 billion, a PE ratio of -21.78 and a beta of 1.54. The stock has a 50 day simple moving average of $25.96 and a two-hundred day simple moving average of $25.12. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Insider Activity

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 120,029 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the transaction, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This trade represents a 65.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total transaction of $979,617.65. Following the completion of the transaction, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 349,073 shares of company stock valued at $9,429,412 in the last ninety days. 7.09% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $36,000. T. Rowe Price Investment Management Inc. grew its stake in shares of Centessa Pharmaceuticals by 7,580.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the period. Finally, Knott David M Jr acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $100,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.